PROVAYBLUE

Peak

methylene blue

NDAINTRAVENOUSSOLUTION
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
13

Clinical Trials (5)

NCT04547127Phase 2Completed

A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)

Started Apr 2020
200 enrolled
COVID-19
NCT02851108Phase 2Completed

Methylene Blue Against Falciparum Malaria in Burkina Faso

Started Oct 2016
100 enrolled
Malaria, Falciparum
NCT02831023Phase 2Completed

Phase 2 Efficacy Study of Primaquine and Methylene Blue

Started Jul 2016
80 enrolled
Malaria
NCT02696928Phase 2Withdrawn

Methylene Blue Against Vivax Malaria in Ethiopia

Started Apr 2016
0
Vivax Malaria
NCT01694966Phase 3Completed

The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy

Started Sep 2013
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers